Repurposing FIB-4 index as a predictor of mortality in patients with hematological malignancies and COVID-19

In this study, we aimed to investigate whether FIB-4 index is useful in predicting mortality in patients with concurrent hematological malignancies and COVID-19. We also aimed to determine the optimal cut-off point for the prediction. This is a single-center retrospective cohort study conducted in D...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2021-09, Vol.16 (9), p.e0257775-e0257775
Main Authors: Sutandyo, Noorwati, Kurniawati, Sri Agustini, Jayusman, Achmad Mulawarman, Syafiyah, Anisa Hana, Pranata, Raymond, Hanafi, Arif Riswahyudi
Format: Article
Language:English
Subjects:
Adult
Biology and Life Sciences
Blood cancer
Cancer
Chemotherapy
Conditional probability
Coronaviruses
COVID-19
COVID-19 - mortality
Enzymes
Ethics
Evaluation
Female
Hematologic Neoplasms - mortality
Hematology
Hemoglobin
Humans
Indonesia
Leukemia
Lymphoma
Male
Medical prognosis
Medical records
Medical research
Medical tests
Medicine and Health Sciences
Mortality
Multivariate analysis
Patient outcomes
Patients
Platelet Count - methods
Polymerase chain reaction
Pulmonology
Regression analysis
Retrospective Studies
Risk factors
RNA-directed DNA polymerase
ROC Curve
SARS-CoV-2 - pathogenicity
Statistical analysis
Thrombocytopenia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this study, we aimed to investigate whether FIB-4 index is useful in predicting mortality in patients with concurrent hematological malignancies and COVID-19. We also aimed to determine the optimal cut-off point for the prediction. This is a single-center retrospective cohort study conducted in Dharmais National Cancer Hospital, Indonesia. Consecutive sampling of adults with hematological malignancies and COVID-19 was performed between May 2020 and January 2021. COVID-19 screening test using the reverse transcriptase polymerase chain reaction (RT-PCR) of nasopharyngeal samples were performed prior to hospitalization for chemotherapy. FIB-4 index is derived from [age (years) × AST (IU/L)]/[platelet count (109/L) × √ALT (U/L)]. The primary outcome of this study is mortality, defined as clinically validated death/non-survivor during a 3-months (90 days) follow-up. There were a total of 70 patients with hematological malignancies and COVID-19 in this study. Median FIB-4 Index was higher in non-survivors (13.1 vs 1.02, p3.85 was independent predictor of mortality in patients with hematological malignancies and COVID-19 infection.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0257775